Targeting Glioblastoma: Advances in Precision Drug Delivery

Glioblastoma Multiforme (GBM) is still one of the most aggressive and resistant brain tumours, and current treatment options provide only minimal improvements in survival. Effective drug delivery is severely hampered by the complexity of GBM, which is defined by its heterogeneity and the Blood-Brain Barrier (BBB). The most recent developments in precision drug delivery technology are examined in this study to address these issues and enhance treatment outcomes for GBM patients. We discuss various innovative approaches, including nanoparticle-based systems, bioconjugates, ligand-targeted therapies, and gene delivery platforms. These technologies are specifically engineered to enhance drug penetration across the BBB, target tumour-specific pathways, and minimise off-target effects, thereby potentially revolutionizing GBM treatment. The review also addresses the challenges associated with clinical translation, including regulatory hurdles, safety concerns, and the need for scalable manufacturing processes. This review endeavours to offer a comprehensive overview of the potential of precision drug delivery to facilitate more personalised and effective GBM therapies in the near future by emphasising the most promising strategies and emergent trends in the field.